Sally Gilbert

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

Stephan Weidinger, Thomas Bieber, Michael J. Cork et al. · British Journal of Dermatology · 2023 · 97 citations · Full text

Correlation of meniscal T2* with multiphoton microscopy, and change of articular cartilage T2 in an ovine model of meniscal repair

Matthew F. Koff, Parina Shah, Sarah L. Pownder et al. · Osteoarthritis and Cartilage · 2013 · 58 citations · Full text

Engineering, Ovine Model, Biomechanics +10

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

Mahdi Saghari, Pim Gal, Sally Gilbert et al. · Clinical Pharmacology & Therapeutics · 2022 · 44 citations · Full text

345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

Stephan Weidinger, Michael J. Cork, Adam Reich et al. · British Journal of Dermatology · 2023 · 11 citations

Clinical Immunology, Immunodeficiencies, Immunology +17